Capecitabine

Reduce the indication-specific dose by 25% at Cockcroft-Gault CrCl 30-50 mL/min. A dose below 30 is not established. Do not manufacture a severe-renal or dialysis schedule from the percentage reduction.

Before initiation, test for DPYD variants unless immediate treatment is necessary. Avoid use in patients with the specified variants causing complete DPD deficiency; no dose has been proven safe for complete deficiency. Partial deficiency requires individualized treatment. Renal adjustment does not replace these safeguards or toxicity management. Monitor hydration and renal function, and review vitamin K antagonist interactions.

Reduce the indication-specific dose by 25% at Cockcroft-Gault CrCl 30-50 mL/min. A dose below 30 is not established. Do not manufacture a severe-renal or dialysis schedule from the percentage reduction.

Before initiation, test for DPYD variants unless immediate treatment is necessary. Avoid use in patients with the specified variants causing complete DPD deficiency; no dose has been proven safe for complete deficiency. Partial deficiency requires individualized treatment. Renal adjustment does not replace these safeguards or toxicity management. Monitor hydration and renal function, and review vitamin K antagonist interactions.

The December 2022 source directs a 25% dose reduction at Cockcroft-Gault CrCl 30-50 mL/min. A dose is not established below 30. Its specific-populations section allows exceptional individualized consideration below 30 only when no treatment alternative exists, with a reduced starting dose and close clinical/biochemical monitoring; it supplies no validated numeric regimen for that exception. Determine the indication-specific starting regimen before applying a renal reduction. The label rounds the recommended dose to the nearest 150 mg to use whole tablets. This is not a universal 950-mg/m2 prescription or a dialysis protocol.

This generic-tablet mirror states that severe impairment below Cockcroft-Gault CrCl 30 mL/min is a contraindication. Its dose section uses a 25% starting-dose reduction at CrCl 30-50. This is retained as source-specific wording, not silently substituted for current selected official labeling.

The separately retrieved 2026 official labels say a dose below 30 has not been established. These statements must remain attributed rather than averaged or converted into an invented severe-renal regimen.

For this metastatic colorectal protocol, indexed eGFR >=60 mL/min/1.73 m2 permits the protocol's full dose. At 45-59, consider a 25% reduction or an alternative protocol; the page explicitly identifies this as a 2023 reference-committee deviation from ADDIKD. At 30-44, consider a 25% reduction or an alternative protocol. At 15-29 or below 15 without kidney replacement therapy, avoid this protocol and use an alternative. Increased toxicity risk is flagged in the intermediate bands. Dialysis requires multidisciplinary oncology, nephrology and/or clinical pharmacology input. These are protocol-specific Australian recommendations, not a substitute for U.S. labeling.

In this post-neoadjuvant breast protocol, indexed eGFR >=60 mL/min/1.73 m2 uses full dose. At 45-59, full dose is listed with increased-adverse-event caution. At 30-44, consider a 25% reduction with increased-adverse-event caution. At 15-29 or below 15 without kidney replacement therapy, avoid treatment under this protocol. Kidney replacement therapy requires multidisciplinary specialist assessment. This differs from the more conservative 45-59 advice in the separate metastatic colorectal protocol; retain treatment intent and protocol identity when comparing them.